Beijing Tong Ren Tang Chinese Medicine Future Growth
Future criteria checks 3/6
Beijing Tong Ren Tang Chinese Medicine is forecast to grow earnings and revenue by 16.5% and 14.8% per annum respectively. EPS is expected to grow by 16.5% per annum. Return on equity is forecast to be 15.7% in 3 years.
Key information
16.5%
Earnings growth rate
16.5%
EPS growth rate
Pharmaceuticals earnings growth | 10.9% |
Revenue growth rate | 14.8% |
Future return on equity | 15.7% |
Analyst coverage | Low |
Last updated | 11 Sep 2024 |
Recent future growth updates
Recent updates
Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) Shares Climb 32% But Its Business Is Yet to Catch Up
Oct 04Earnings Troubles May Signal Larger Issues for Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Shareholders
Sep 06Is There An Opportunity With Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) 31% Undervaluation?
Sep 02Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) 28% Share Price Plunge Could Signal Some Risk
Feb 05Calculating The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)
Jan 03A Look At The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)
Sep 28Here's Why We Think Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Might Deserve Your Attention Today
Jul 12Is Now The Time To Put Beijing Tong Ren Tang Chinese Medicine (HKG:3613) On Your Watchlist?
Mar 29Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Has Announced That It Will Be Increasing Its Dividend To HK$0.28
Apr 28Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Will Pay A Larger Dividend Than Last Year At HK$0.28
Mar 25Are Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Investors Paying Above The Intrinsic Value?
Oct 27Beijing Tong Ren Tang Chinese Medicine's (HKG:3613) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Apr 28Read This Before Selling Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Shares
Mar 11What Type Of Returns Would Beijing Tong Ren Tang Chinese Medicine's(HKG:3613) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Feb 04Should Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Be Part Of Your Dividend Portfolio?
Jan 18Could The Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Ownership Structure Tell Us Something Useful?
Dec 29Read This Before Selling Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Shares
Dec 11Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Nov 23Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 2,011 | 738 | N/A | N/A | 1 |
12/31/2025 | 1,850 | 671 | N/A | 657 | 2 |
12/31/2024 | 1,628 | 559 | N/A | 681 | 2 |
6/30/2024 | 1,377 | 494 | -384 | -358 | N/A |
3/31/2024 | 1,451 | 517 | 28 | 52 | N/A |
12/31/2023 | 1,525 | 540 | 439 | 461 | N/A |
9/30/2023 | 1,721 | 619 | 552 | 584 | N/A |
6/30/2023 | 1,918 | 697 | 665 | 706 | N/A |
3/31/2023 | 1,824 | 672 | 587 | 627 | N/A |
12/31/2022 | 1,731 | 646 | 509 | 547 | N/A |
9/30/2022 | 1,605 | 601 | 636 | 665 | N/A |
6/30/2022 | 1,478 | 555 | 763 | 782 | N/A |
3/31/2022 | 1,517 | 582 | 758 | 779 | N/A |
12/31/2021 | 1,556 | 608 | 754 | 777 | N/A |
9/30/2021 | 1,504 | 595 | 575 | 596 | N/A |
6/30/2021 | 1,452 | 583 | 397 | 414 | N/A |
3/31/2021 | 1,384 | 563 | 250 | 265 | N/A |
12/31/2020 | 1,315 | 542 | 103 | 116 | N/A |
9/30/2020 | 1,246 | 483 | 198 | 213 | N/A |
6/30/2020 | 1,178 | 424 | 294 | 310 | N/A |
3/31/2020 | 1,305 | 490 | 414 | 430 | N/A |
12/31/2019 | 1,433 | 556 | 534 | 551 | N/A |
9/30/2019 | 1,505 | 594 | 553 | 568 | N/A |
6/30/2019 | 1,577 | 632 | 572 | 585 | N/A |
3/31/2019 | 1,546 | 601 | N/A | N/A | N/A |
12/31/2018 | 1,514 | 581 | 524 | 578 | N/A |
9/30/2018 | 1,466 | 552 | N/A | N/A | N/A |
6/30/2018 | 1,402 | 540 | 447 | 507 | N/A |
3/31/2018 | 1,330 | 516 | N/A | N/A | N/A |
12/31/2017 | 1,266 | 490 | N/A | 469 | N/A |
9/30/2017 | 1,212 | 469 | N/A | N/A | N/A |
6/30/2017 | 1,166 | 449 | N/A | 465 | N/A |
3/31/2017 | 1,134 | 444 | N/A | N/A | N/A |
12/31/2016 | 1,084 | 420 | N/A | 468 | N/A |
9/30/2016 | 1,063 | 431 | N/A | N/A | N/A |
6/30/2016 | 1,028 | 410 | N/A | 415 | N/A |
3/31/2016 | 1,002 | 380 | N/A | N/A | N/A |
12/31/2015 | 970 | 354 | N/A | 354 | N/A |
9/30/2015 | 939 | 337 | N/A | N/A | N/A |
6/30/2015 | 881 | 320 | N/A | 316 | N/A |
3/31/2015 | 834 | 304 | N/A | N/A | N/A |
12/31/2014 | 761 | 287 | N/A | 245 | N/A |
9/30/2014 | 733 | 286 | N/A | N/A | N/A |
6/30/2014 | 699 | 267 | N/A | 202 | N/A |
3/31/2014 | 652 | 249 | N/A | N/A | N/A |
12/31/2013 | 614 | 220 | N/A | 143 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 3613's forecast earnings growth (16.5% per year) is above the savings rate (2.3%).
Earnings vs Market: 3613's earnings (16.5% per year) are forecast to grow faster than the Hong Kong market (11.6% per year).
High Growth Earnings: 3613's earnings are forecast to grow, but not significantly.
Revenue vs Market: 3613's revenue (14.8% per year) is forecast to grow faster than the Hong Kong market (7.8% per year).
High Growth Revenue: 3613's revenue (14.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 3613's Return on Equity is forecast to be low in 3 years time (15.7%).
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/19 16:38 |
End of Day Share Price | 2024/12/19 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Beijing Tong Ren Tang Chinese Medicine Company Limited is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Yanyin Zhu | China International Capital Corporation Limited |
null null | CMB International Securities Limited |
Christina Chen | HSBC |